Kinderwunsch und Multiple Sklerose

Lernziele

Kenntnisse über beidseitige Wechselwirkung von Multiple(r) Sklerose und Schwangerschaft Kenntnisse über aktuelle Datenlage zur immunmodulatorischen Therapie für MS-Patienten mit Kinderwunsch Therapiemöglichkeiten post partum

Literatur

• 1 Hellwig K, Brune N, Haghikia A. et al . Reproductive counselling, treatment and course of pregnancy in 73 German MS patients.  Acta Neurol Scand. 2008;  118 24-28
• 2 Vukusic S, Hutchinson M, Hours M. The Pregnancy In Multiple Sclerosis Group, Pregnancy In Multiple Sclerosis Group et al . Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.  Brain. 2004;  127 1353-1360
• 3 Park-Wyllie L, Mazzotta P, Pastuzak A. et al . Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies.  Teratology. 2000;  62 385-392
• 4 Hoffmann L A, Kumpfel T, Heer I. et al . [Pregnancy and immunomodulatory therapy in multiple sclerosis patients].  Nervenarzt. 2006;  77 663-668
• 5 Koch M, Uyttenboogaart M, Heersema D. et al . Parity and secondary progression in multiple sclerosis.  J Neurol Neurosurg Psychiatry. 2009;  80 676-678
• 6 D’hooghe M B, Nagels G, Uitdehaag B M. Long-term effects of childbirth in MS.  J Neurol Neurosurg Psychiatry. 2010;  81 38-41
• 7 Wegmann T G, Lin H, Guilbert L. et al . Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?.  Immunol Today. 1993;  14 353-356
• 8 Sánchez-Ramón S, Navarro A J, Aristimuño C. et al . Pregnancy-induced expansion of regulatory T-lymphocytes may mediate protection to multiple sclerosis activity.  Immunol Lett. 2005;  96 195-201
• 9 Airas L, Saraste M, Rinta S. et al, Finnish Multiple Sclerosis and Pregnancy Study Group . Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells.  Clin Exp Immunol. 2008;  151 235-243
• 10 Airas L, Nikula T, Huang Y H. et al . Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G.  J Neuroimmunol. 2007;  187 205-211
• 11 Doria A, Iaccarino L, Arienti S. et al . Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases.  Reprod Toxicol. 2006;  22 234-241
• 12 Vukusic S, Ionescu I, El-Etr M. et al, Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis Study Group . The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART’MUS) trial: rationale, objectives and state of advancement.  J Neurol Sci 2009. 15;  286 114-118
• 13 Cocco E, Sardu C, Gallo P. et al, the FEMIMS group* . Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.  Mult Scler. 2008;  14 1225-1233
• 14 Katsifis G E, Tzioufas A G. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.  Lupus. 2004;  13 673-678
• 15 Kelly V M, Nelson L M, Chakravarty E F. Obstetric outcomes in women with multiple sclerosis and epilepsy.  Neurology. 2009;  73 1831-1836
• 16 Dahl J, Myhr K M, Daltveit A K. et al . Pregnancy, delivery, and birth outcome in women with multiple sclerosis.  Neurology. 2005;  65 1961-1963
• 17 Dahl J, Myhr K M, Daltveit A K. et al . Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis.  J Neurol. 2008;  255 623-627
• 18 Scott J R. Risks to the children born to mothers with autoimmune diseases.  Lupus. 2002;  11 655-660
• 19 Boskovic R, Wide R, Wolpin J. et al . The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort.  Neurology. 2005;  65 807-811
• 20 Patti F, Cavallaro T, Lo Fermo S. et al . Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?.  J Neurol. 2008;  255 1250-1253
• 21 Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.  Mult Scler. 2009;  15 1037-1042
• 22 Coyle P K, Christie S, Fodor P. et al . Multiple sclerosis gender issues: clinical practices of women neurologists.  Mult Scler. 2004;  10 582-588
• 23 Sandberg-Wollheim M, Frank D, Goodwin T M. et al . Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.  Neurology. 2005;  65 802-806
• 24 de Santis M, Straface G, Cavaliere A F. et al . The first case of mitoxantron exposure in early pregnancy.  Neuro Toxicology. 2007;  28 696-697
• 25 Briggs G G, Freemann R K, Yaffe S J. Classification of drugs for teratogenic risk: an anachronistic way of counselling: a reply to Merlob and Stahl.  Birth defects Res A. 2003;  67 207-208
• 26 Hellwig K, Agne H, Gold R. Interferon beta, birth weight and pregnancy in multiple sclerosis.  J Neurol. 2009;  256 830-831
• 27 Gucev Z S, Kirovski I, Jancevska A. et al . Papillorenal syndrome after Beta-interferon treatment in pregnancy.  Ren Fail. 2009;  31 602-605
• 28 Sandberg-Wollheim M, Alteri E, Stam Moraga M. et al . Subcutanous interferon beta 1-a treatment and pregnancy outcomes in patients with MS.  Neurology. 2010;  74 (Suppl. 2) 9 S.40.005
• 29 Coyle P K, Johnson K, Pardo L. et al . Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone).  Neurology. 2003;  60 A60
• 30 Polman C H, O’Connor P W, Havrdova E. et al, AFFIRM Investigators . A randomized placebo controlled trial of natalizumab for relapsing remitting multiple sclerosis.  N Engl J Med. 2006;  354 899-910
• 31 Hellwig K, Haghikia A, Gold R. Motherhood and Natalizumab-effects of natalizumab therapy on pregnancy outcome and disease activity during pregnancy.  Neurology. 2010;  74 (Suppl. 2) 9 P 06.168
• 32 Azuno Y, Kaku K, Fujita N. Mitoxantron and etoposid in breastmilk.  Am J Hematol. 1995;  48 131-132
• 33 Giacalone P L, Benos P, Rousseau O. Chemotherapy for breast carcinoma during pregnancy.  Cancer. 1999;  86 2266-2272
• 34 Reynoso E E, Huerta F. Acute leukemia and pregnancy – fatal fetal outcome after exposure to idarubicin during the second trimester.  Acta Oncol. 1994;  33 703-716
• 35 Blumenfeld Z, Shapiro D, Shteinberg M. et al . Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.  Lupus. 2000;  9 401-405
• 36 Telez N, Gris J, Tintore M. et al . Prevention of persistent ovarian failure after mitoxantrone in women with MS. Design of a treatment protocol with triptorelin.  Multiple sclerosis. 2006;  12 (Suppl. 1) P 758
• 37 Thomas W. Hale, Medication and Mothers Milk, 13th edition. Hale Publishing 2006: Seite 437 und 504
• 38 Kumar A R, Hale T W, Mock R E. Transfer of interferon alfa into human breast milk.  J Hum Lact. 2000;  16 226-228
• 39 Azuno Y, Kaku K, Fujita N. et al . Mitoxantrone and etoposide in breast milk.  Am J Hematol. 1995;  48 131-132
• 40 De Seze J, Chapelotte M, Delalande S. et al . Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis.  Mult Scler. 2004;  10 596-597
• 41 Achiron A, Kishner I, Dolev M. et al . Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis.  J Neurol. 2004;  251 1133-1137
• 42 Haas J, Hommes O R. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis.  Mult Scler. 2007;  13 900-908
• 43 Hellwig K, Beste C, Schimrigk S. et al . Immunomodulation and postpartum relapses in patients with multiple sclerosis.  Ther Adv Neurol Dis. 2009;  2 7-11
• 44 Gold R, Stangel M, Dalakas M C. Drug Insight: The use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues.  Nat Clin Pract Neurol. 2007;  3 36-44
• 45 Langer-Gould A, Huang S M, Gupta R. et al . Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.  Arch Neurol. 2009;  66 958-963
• 46 Langer-Gould A, Gupta R, Huang S. et al . Interferon-gamma-producing T cells, pregnancy, and postpartum relapses of multiple sclerosis.  Arch Neurol. 2010;  67 51-57
• 47 Hellwig K, Haghikia A, Agne H. et al . Protective effect of breastfeeding in postpartum relapse rate of mothers with Multiple Sclerosis.  Arch Neurol. 2009;  66 1580-1581
• 48 Portaccio E, Ghezzi A, Hakiki B. et al . Breastfeeding is not related with the risk of postpartum relapses in women with multiple sclerosis.  Neurology. 2010;  74 (Suppl. 2) S40.003
• 49 Greenberger P A, Odeh Y K, Frederiksen M C. et al . Pharmacokinetics of prednisolone transfer to breast milk.  Clin Pharmacol Ther. 1993;  53 324-328
• 50 Laplaud D A, Leray E, Barriere P. et al . Increase in multiple sclerosis relapse rate following in vitro fertilization.  Neurology. 2006;  66 1280-1281
• 51 Hellwig K, Beste C, Brune N. et al . Increased MS relapse rate during assisted reproduction technique.  J Neurol. 2008;  255 592-593
• 52 Hellwig K, Schimrigk S, Beste C. et al . Increase of relapse rate during assisted reproduction technique in patients with multiple sclerosis.  Eur Neurol. 2008;  61 65-68
• 53 Buljevac D, Hop W C, Reedeker W. et al . Self reported stressful life events and exacerbations in multiple sclerosis: a prospective study.  BMJ. 2003;  327 646
• 54 Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis.  J Neurol. 2009;  257 580-583